Souseikai Fukuoka Mirai Hospital
Fukuoka, 813-0017, Japan
NCT Number: NCT06594159
The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants. Blood tests will be performed to check how much LY4065967 and rosuvastatin get into the bloodstream and how long it takes the body to eliminate it. This is a 3-part study and will last approximately 2 weeks excluding screening period for each part.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Fukuoka, 813-0017, Japan
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered orally
Administered orally
Administered orally
Time frame: Baseline to 7 Days
Part A: A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline to 12 Days
Part B: A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Predose on Day 1 Through 72 Hours Post-Dose
Part D: PK: Cmax of Rosuvastatin
Time frame: Predose on Day 1 Through 72 Hours Post-Dose
Part D: PK: AUC of Rosuvastatin
Time frame: Predose on Day 1 Through 48 Hours Post-Dose
Part A: PK: Cmax of LY4065967
Time frame: Predose on Day 1 Through Day 9
Part B: PK: Cmax of LY4065967
Time frame: Predose on Day 1 Through 48 Hours Post-Dose
Part A and B: PK: AUC of LY4065967
Time frame: Day 5 Through Day 11
Part D: PK: Cmax of LY4065967
Time frame: Day 5 Through Day 11
Part D: PK: AUC of LY4065967
Eli Lilly and Company
Industry
A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of LY4065967, to Evaluate the Effect of LY4065967 on the Pharmacokinetics of Rosuvastatin in Healthy Japanese Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details